Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 11
Submit an article Journal homepage
333
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells

José A. RodríguezMolecular Biology Institute, University of California, Los Angeles, CA, USA;Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
Rosendo Luria-PérezDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA;Unit of Investigative Research on Oncological Disease, Children's Hospital of Mexico “Federico Gómez”, Mexico City, Mexico
,
Héctor E. López-ValdésDepartment of Neurology, University of California, Los Angeles, CA, USA
,
David CaseroDepartment of Molecular Cell and Developmental Biology, University of California, Los Angeles, CA, USA
,
Tracy R. DanielsDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
Shabnum PatelDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
David AvilaDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
Richard LeuchterDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
Sokuntheavy SoDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
Elizabeth Ortiz-SánchezDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
,
Benjamin BonavidaDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, USA;Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA
,
Otoniel Martínez-MazaDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, USA;Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA;Department of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA;Department of Epidemiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
,
Andrew C. CharlesDepartment of Neurology, University of California, Los Angeles, CA, USA
,
Matteo PellegriniDepartment of Molecular Cell and Developmental Biology, University of California, Los Angeles, CA, USA
,
Gustavo HelgueraDivision of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA
&
Manuel L. PenichetMolecular Biology Institute, University of California, Los Angeles, CA, USA;Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, CA, USA;Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, USA;Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USACorrespondence[email protected]
 show all
Pages 2169-2178 | Received 12 Dec 2010, Accepted 05 Jun 2011, Published online: 28 Aug 2011

References

  • Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999;31:1111–1111.
  • Daniels TR, Delgado T, Rodriguez JA, . The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144–144.
  • Ciechanover A, Schwartz AL, Lodish HF. Sorting and recycling of cell surface receptors and endocytosed ligands: the asialoglycoprotein and transferrin receptors. J Cell Biochem 1983;23:107–107.
  • Larrick JW, Enns C, Raubitschek A, . Receptor-mediated endocytosis of human transferrin and its cell surface receptor. J Cell Physiol 1985;124:283–283.
  • Das Gupta A, Shah VI. Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Hematol Pathol 1990;4:37–37.
  • White S, Taetle R, Seligman PA, . Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res 1990;50:6295–6295.
  • Kasibhatla S, Jessen KA, Maliartchouk S, . A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 2005;102:12095–12095.
  • Horonchik L, Wessling-Resnick M. The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem Biol 2008;15:647–647.
  • Ng PP, Dela Cruz JS, Sorour DN, . An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci USA 2002;99:10706–10706.
  • Callens C, Moura IC, Lepelletier Y, . Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 2008;22:42–42.
  • Daniels TR, Delgado T, Helguera G, . The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006;121:159–159.
  • Crepin R, Goenaga AL, Jullienne B, . Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res 2010;70:5497–5497.
  • Peer D, Karp JM, Hong S, . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–751.
  • Ng PP, Helguera G, Daniels TR, . Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 2006;108:2745–2745.
  • Laubach JP, Richardson PG, Anderson KC. The evolution and impact of therapy in multiple myeloma. Med Oncol 2010;27(Suppl. 1):S1–S6.
  • Daniels TR, Ng PP, Delgado T, . Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol Cancer Ther 2007;6:2995–2995.
  • Rodriguez JA, Helguera G, Daniels TR, . Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release 2007;124:35–35.
  • Ortiz-Sanchez E, Daniels TR, Helguera G, . Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia 2009;23:59–59.
  • Xia F, Wang X, Wang YH, . Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995;55:12–12.
  • Lu TP, Lai LC, Lin BI, . Distinct signaling pathways after higher or lower doses of radiation in three closely related human lymphoblast cell lines. Int J Radiat Oncol Biol Phys 2010;76:212–212.
  • Simunek T, Boer C, Bouwman RA, . SIH—a novel lipophilic iron chelator—protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J Mol Cell Cardiol 2005;39:345–345.
  • Beltran-Parrazal L, Lopez-Valdes HE, Brennan KC, . Mitochondrial transport in processes of cortical neurons is independent of intracellular calcium. Am J Physiol Cell Physiol 2006;291:C1193–1197.
  • Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol 2008;438:77–77.
  • Feo-Zuppardi FJ, Taylor CW, Iwato K, . Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 1992;80:2843–2843.
  • Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003;4:277–277.
  • Breuer W, Epsztejn S, Cabantchik ZI. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett 1996;382:304–304.
  • Lin SM, Du P, Huber W, . Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 2008;36:e11.
  • Daniels TR, Neacato II, Rodriguez JA, . Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia 2010;24:1555–1555.
  • Saletta F, Rahmanto YS, Noulsri E, . Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol 2010;77:443–443.
  • Richardson DR, Kalinowski DS, Lau S, . Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 2009;1790:702–702.
  • Gao J, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood 2001;98:842–842.
  • Suzuki E, Daniels TR, Helguera G, . Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol 2010;36:1299–1299.
  • Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res 1986;46:1759–1759.
  • Moura IC, Lepelletier Y, Arnulf B, . A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004;103:1838–1838.
  • Tacchini L, Bianchi L, Bernelli-Zazzera A, . Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274:24142–24142.
  • Piccinelli P, Samuelsson T. Evolution of the iron-responsive element. RNA 2007;13:952–952.
  • Templeton DM, Liu Y. Genetic regulation of cell function in response to iron overload or chelation. Biochim Biophys Acta 2003;1619:113–113.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.